natgillin/translations-raw huggingface dataset:
Find a well-lit area without significant distraction for the injection. 
Nađite dobro osvijetljeno i mirno okruženje gdje možete neometano primijeniti injekciju.
Further, it was demonstrated that interferon alfa is able to decrease the mutated JAK2V617F allele burden in patients with polycythaemia vera (a V617F point mutation in the JAK2 kinase is a hallmark of polycythaemia vera and is present in approximately 95% of patients). 
Nadalje, dokazano je da interferon alfa može smanjiti opterećenje mutiranim alelom JAK2V617F kod bolesnika s policitemijom verom (točkasta mutacija V617F kod JAK2 kinaze je obilježje policitemije vere te je prisutna u približno 95% bolesnika).
Administration of 180 micrograms of pegylated interferon alfa-2a once weekly for 4 weeks in healthy male subjects did not show any effect on mephenytoin, dapsone, debrisoquine and tolbutamide pharmacokinetics profiles, suggesting that pegylated interferon alfa-2a has no effect on in vivo metabolic activity of cytochrome P450 (CYP) 3A4, 2C9, 2C19 and 2D6 isozymes. 
Primjena 180 mikrograma pegiliranog interferona alfa-2a jedanput na tjedan tijekom 4 tjedna u zdravih muških ispitanika nije pokazala nikakav učinak na farmakokinetičke profile mefenitoina, dapsona, debrizokina i tolbutamida, ukazujući da pegilirani interferon alfa-2a nema učinka na in vivo metaboličku aktivnost izoenzime (CYP) 3A4, 2C9, 2C19 i 2D6 citokroma P450 . U istom ispitivanju,
If adverse events develop during therapy, the administered dose should be reduced or treatment discontinued temporarily until adverse events abate; further, treatment should be re-initiated with a lower dose than the dose that caused adverse events. 
Ako se tijekom terapije razviju štetni događaji, primijenjenu dozu treba smanjiti ili privremeno prekinuti liječenje dok se štetni događaji ne povuku.
Besremi contains benzyl alcohol 
Besremi sadrži benzilni alkohol
This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially ‘sodiumfree'. 
Ovaj lijek sadrži manje od 1 mmol natrija (23 mg) po ml, tj. zanemarive količine natrija.
19 (10.7) 6.0 n.r. 
19 (10,7) 6,0 n.z.
Based on single dose data, clearance was similar in patients with severe renal impairment not on haemodialysis and in patients who received haemodialysis. 
Na temelju podataka o jednokratnoj dozi, klirens je bio sličan u bolesnika s teškim oštećenjem bubrega koji nisu na hemodijalizi te u bolesnika koji su primili hemodijalizu.
Correct the dose if necessary by turning the dose knob. 
Ako je potrebno, ispravite dozu okretanjem kotačića za odabir doze.
The use of ropeginterferon alfa-2b is associated with skin disorders (pruritus, alopecia, rash, erythema, psoriasis, xeroderma, dermatitis acneiform, hyperkeratosis, hyperhydrosis). 
Uporaba ropeginterferon alfa-2b povezana je s kožnim poremećajima (pruritus, alopecija, osip, eritem, psorijaza, kseroderma, akneiformni dermatitis, hiperkeratoza, hiperhidroza).
Raynaud's phenomenon, hypertension, haematoma, flushing 
Raynaudov fenomen, hipertenzija, hematom, navale crvenila
The disease response (defined as haematocrit <45% without phlebotomy [at least 3 months since last phlebotomy], platelets <400 x 109/L and leukocytes <10 x 109/L after 12 months of treatment) was 43.1% [53/123 of patients] in the ropeginterferon alfa-2b arm after 12 months of treatment. 
Odgovor na bolest (definiran kao vrijednost hematokrita < 45% bez flebotomije [barem 3 mjeseca od posljednje flebotomije], trombociti <400 x 109/l i leukociti <10 x 109/l nakon 12 mjeseci liječenja uključivao je 43,1% [53/123 bolesnika] u skupini koja je primala ropeginterferon alfa-2b (43,1%
Arthralgia 23 (12.9) 8.5 1 (4.3)* 4 (17.4) 4 (17.4) Fatigue 
Trombocitopenija 33 (18,5) 15,0 4 (12,1%)* 13 (39,4) 3 (9,1) Artralgija
Ropeginterferon alfa-2b is found mainly in the bloodstream and extracellular fluid as seen by the volume of distribution at steady-state (Vd) of 6.6 to 17 litres in patients after subcutaneous administration (dose range 50 - 450 micrograms). 
Ropeginterferon alfa-2b nalazi se uglavnom u krvotoku i izvanstaničnoj tekućini što se može vidjeti prema volumenu distribucije u stanju dinamičke ravnoteže (Vd) od 6,6 do 17 litara u bolesnika nakon supkutane primjene (raspon doze 50 - 450 mikrograma).
Only limited pharmacokinetic data are available from the use of ropeginterferon alfa-2b in the elderly. 
Dostupni su samo ograničeni farmakokinetički podaci o uporabi ropeginterferona alfa-2b u starijih osoba.
Adjustments in the recommended dose for ropeginterferon alfa-2b are not necessary when starting therapy in elderly patients (see section 5.2). 
Prilagodbe u preporučenoj dozi ropeginterferona alfa-2b nisu potrebne kada se počinje s terapijom u starijih bolesnika (vidjeti dio 5.2).
After subcutaneous multiple dose administration (dose range 50 - 450 micrograms), the terminal halflife of ropeginterferon alfa-2b in patients is approximately 6 to 10 days and the clearance of ropeginterferon alfa-2b is 0.023 to 0.061 L/h. 
Nakon višekratnog supkutanog doziranja (raspon doza od 50 do 450 mikrograma), terminalni poluvijek ropeginterferona alfa-2b u bolesnika iznosi približno 6 do 10 dana, a klirens ropeginterferona alfa-2b je 0,023 do 0,061 l/sat.
In the clinical development program of ropeginterferon alfa-2b, two cases of serious depression (1.1%; incidence rate: 0.4 events/100 patients per year) occurred. 
U programu kliničkog razvoja ropeginterferona alfa-2b dogodila su se dva slučaja ozbiljne depresije (1,1%; stopa incidencije: 0,4 događaja/100 bolesnika po godini).
The recommended posology for the titration phase of ropeginterferon alfa-2b (see section 4.2) results in a prolonged time to reach the individual optimal dose compared to hydroxycarbamide. 
Preporučeno doziranje za fazu titracije ropeginterferona alfa-2b (vidjeti dio 4.2) rezultira u produljenom vremenu dostizanja individualne optimalne doze u usporedbi s hidroksikarbamidom.
If the pre-filled pen is used for the first time, the pen is prepared for injection by turning the dose knob until the symbol of a “drop” in the display window is seen. 
Ako se napunjena brizgalica koristi po prvi put, brizgalica se priprema za injekciju okretanjem kotačića za odabir doze dok se ne uoči simbol „kapljice“ na prozorčiću za prikaz doze.
Besremi 250 micrograms/0.5 mL 
Besremi 250 mikrograma/0,5 ml
Patients should have eye examinations before and during ropeginterferon alfa-2b therapy, specifically in those patients with retinopathy associated disease such as diabetes mellitus or hypertension. 
Bolesnicima treba pregledati oči prije i tijekom terapije ropeginterferonom alfa-2b, posebice kod onih bolesnika s retinopatijom povezanom s bolestima poput dijabetesa melitusa ili hipertenzije.
In addition, dry mouth could have a damaging effect on teeth and mucous membranes of the mouth during long-term treatment with ropeginterferon alfa-2b. 
Osim toga, suha usta mogu imati štetan učinak na zube i sluznicu usta tijekom dugotrajnog liječenja ropeginterferonom alfa-2b.
**e.g. urticaria, angioedema, bronchoconstriction or anaphylaxis. 
**npr. urtikarija, angioedem, bronhokonstrikcija ili anafilaksija.
• Unscrew the needle and dispose of it appropriately. 
• Odvijte iglu i zbrinite je na odgovarajući način.
Keep the pre-filled pen in the outer carton in order to protect from light. 
Napunjenu brizgalicu čuvati u vanjskoj kutiji radi zaštite od svjetlosti.
Your doctor will tell you where you have to inject it. Possible injection sites are the belly (more than five centimeters away from the belly button) or the thigh. 
Moguća mjesta injiciranja su trbuh (mjesto mora biti udaljeno više od 5 cm od pupka) ili na bedru.
Studies with a similar interferon alfa medicinal product (pegylated interferon alfa-2a) indicated that the kidney is a major organ for excretion of radiolabelled metabolic products (study in rats) and that the systemic clearance of pegylated interferon alfa-2a in humans is about 100-fold lower compared to the native, unpegylated interferon alfa-2a. 
Ispitivanja sa sličnim lijekom koji sadrži interferon alfa (pegilirani interferon alfa-2a) ukazala su na to da je bubreg glavni organ za izlučivanje radio označenih metaboličkih produkata (ispitivanje na štakorima) i da je sistemski klirens pegiliranog interferona alfa-2a u ljudi otprilike 100 puta niži u usporedbi s nativnim nepegeiliranim interferonom alfa-2a.
The dose can be set in steps of 50 micrograms by rotating the dose knob. 
Doza se može podesiti u koracima od 50 mikrograma rotiranjem kotačića za odabir doze.
Interferon alfa has shown to influence the activity of cytochrome P450 (CYP) isozymes CYP1A2 and CYP2D6. 
Interferon alfa je pokazao utjecaj na aktivnosti citokroma P450 (CYP) izoenzima CYP1A2 i CYP2D6.
An abortifacient effect was reported in primates receiving other interferon alfa medicinal products. 
Abortivni učinak zabilježen je u primata koji primaju druge lijekove koji sadrže interferon alfa.
not known 
nepoznato
The attachment of interferon alfa-2b to a high molecular weight (40 kDa) branched polyethylene glycol moiety is considered as the main reason for the differences in the elimination compared to unpegylated interferons. 
Dodavanje interferona alfa-2b razgranatom polietilenglikolnom dijelu molekule s visokom molekularnom težinom (40 kDa) smatra se glavnim razlogom za razlike u eliminaciji u usporedbi s nepegiliranim interferonima.
Please read this leaflet carefully before using the Besremi 500 micrograms pre-filled pen. 
Pažljivo pročitajte ovu uputu prije nego počnete koristiti Besremi 500 mikrograma napunjenu brizgalicu.
Ropeginterferon alfa-2b must not be administered in patients with existence of or history of severe psychiatric disorders, particularly severe depression, suicidal ideation or suicide attempt (see section 4.3). 
Ropeginterferon alfa-2b ne smije se primjenjivati u bolesnika koji trenutno ili u anamnezi imaju teške psihijatrijske poremećaje, posebice tešku depresiju, suicidalnu ideaciju ili pokušaj samoubojstva (vidjeti dio 4.3).
Hydroxycarbamide treatment-naïve (n=160) or hydroxycarbamide treated (n=94) patients were randomised to receive ropeginterferon alfa-2b or hydroxycarbamide. 
Bolesnici koji nisu prethodno primali hidroksikarbamid (n=160) ili bolesnici koji su liječeni hidroksikarbamidom (n=94) bili su randomizirani za primanje ropeginterferona alfa-2b ili hidroksikarbamida.
• Alcohol wipe 
• alkoholnu maramicu
Interferon alfa was shown to have an inhibitory effect on the proliferation of hematopoietic and bone marrow fibroblast progenitor cells and antagonised the action of growth factors and other cytokines that have a role in the development of myelofibrosis. 
Dokazano je da interferon alfa ima inhibitorni učinak na proliferaciju hematopoetskih te progenitorskih stanica fibroblasta koštane srži te antagonistički djelovanju čimbenika rasta i drugih citokina koji imaju ulogu u razvoju mijelofibroze.
The absorption of ropeginterferon alfa-2b is sustained in patients with peak serum concentrations reached after 3 to 6 days. 
Apsorpcija ropeginterferona alfa-2b održana je u bolesnika, a vršne serumske koncentracije se postižu nakon 3 do 6 dana.
Inspect the solution before use. 
Prije uporabe pregledajte otopinu.
An open-label, phase IIIb extension study (CONTINUATION-PV) enrolled 171 adult polycythaemia vera patients who previously completed the PROUD-PV Study to evaluate the long-term efficacy and safety of ropeginterferon alfa-2b. 
Otvoreni produžetak ispitivanja faze IIIb (CONTINUATION-PV) uključivao je 171 odraslog bolesnika s policitemijom verom koji su prethodno dovršili ispitivanje PORUD-PV za procjenu dugotrajne djelotvornosti i sigurnosti ropeginterferona alfa-2b.
An open label, randomised phase III study (PROUD-PV) evaluated the efficacy and safety of ropeginterferon alfa-2b in comparison to hydroxycarbamide in 254 adult polycythaemia vera patients (randomisation 1:1). 
U otvorenom, randomiziranom kliničkom ispitivanju faze III (PROUD-PV) procjenjivala se djelotvornost i sigurnost ropeginterferona alfa-2b u usporedbi s hidroksikarbamidom u 254 odrasla bolesnika s policitemijom verom (randomizacija 1:1).
Ninety-five patients continued to receive ropeginterferon alfa-2b (from 50 to 500 micrograms administered subcutaneously every two, three or four weeks). 
Devedeset i pet posto bolesnika nastavilo je primati ropeginterferon alfa-2b (od 50 do 500 mikrograma primijenjeno supkutano svaka 2, 3 ili 4 tjedna).
At doses up to 100 micrograms, the same pen can be used twice. 
Pri dozama do 100 mikrograma ista brizgalica može se koristiti dva puta.
Solution for injection in pre-filled pen (injection). 
Otopina za injekciju u napunjenoj brizgalici (injekcija).
Female n (%) Male n (%) 
Žene n (%) Muškarci n (%)
Narcotics, hypnotics or sedatives must be administered with caution when used concomitantly with ropeginterferon alfa-2b. 
Narkotike, hipnotike ili sedative treba primjenjivati s oprezom kada se primjenjuju istodobno s ropeginterferonom alfa-2b.
Treatment should be initiated under supervision of a physician experienced in the management of the disease. 
4.2 Doziranje i način primjene Liječenje treba započeti pod nadzorom liječnika iskusnog u liječenju bolesti.
At doses up to 250 micrograms, the same pen can be used twice. 
Pri dozama do 250 mikrograma ista brizgalica može se koristiti dva puta.
Inter-subject variability was observed with 25% and 35% for AUC and Cmax, respectively, in healthy volunteers. 
Kod zdravih dobrovojaca je između ispitanika uočena varijabilnost od 25% i 35% za AUC odnosno za Cmax.
How to use Besremi 
Kako primjenjivati Besremi
Besremi 500 micrograms/0.5 mL 
Besremi 500 mikrograma/0,5 ml
In a clinical study in polycythaemia vera, the end of the mean individual titration phase for ropeginterferon alfa-2b was reached after approximately 3.7 months, for hydroxycarbamide after approximately 2.6 months of treatment. 
U kliničkom ispitivanju policitemije vere, trajanje prosječne faze individualne titracije ropeginterferona alfa-2b iznosilo je približno 3,7 mjeseci, a za hidroksikarbamid približno 2,6 mjeseci liječenja.
19 (10.7) 6.3 n.r. 
19 (10,7) 6,3 n.z.
From mass balance, tissue distribution and whole body autoradioluminography studies performed in rats, it was shown that a similar interferon alfa medicinal product (pegylated interferon alfa-2a) was distributed to the liver, kidney and bone marrow in addition to being highly concentrated in the blood. 
Iz masene ravnoteže, distribucije u tkiva i ispitivanja autoradioluminografije cijelog tijela u ispitivanjima na štakorima dokazano je da se lijek koji sadrži interferon alfa (pegilirani inteferon alfa2a) distribuirao u jetru, bubrege i koštanu srž pored njegove visoke koncentracije u krvi.
Metabolism and nutrition disorders common hypertriglyceridaemia, decreased appetite 
Poremećaji metabolizma i prehrane često hipertrigliceridemija, smanjeni apetit
Dental and gum disorders, which may lead to loss of teeth, can occur with interferon medicines. 
Poremećaji zubi i desni, koji mogu uzrokovati gubitak zubi, mogu se javiti kod primjene lijekova koji sadrže interferon.
Each pack contains 1 pre-filled pen and 2 injection needles. 
Jedno pakiranje sadrži 1 napunjenu brizgalicu i 2 igle za injekcije.
Store the pen in the outer carton in the refrigerator. 
Čuvajte brizgalicu u vanjskoj kutiji u hladnjaku.
The Besremi 500 micrograms pre-filled pen can be used to inject doses of 50, 100, 150, 200, 250, 300, 350, 400, 450 and 500 micrograms. 
Besremi 500 mikrograma napunjena brizgalica može se upotrijebiti za ubrizgavanje doza od 50, 100, 150, 200, 250, 300, 350, 400, 450 i 500 mikrograma.
Dental and periodontal disorders, which may lead to loss of teeth, have been reported with other interferon alfa medicinal products (see section 4.8). 
Zubni i parodontni poremećaji, koji mogu dovesti do gubitka zubi, prijavljeni su kod drugih lijekova koji sadrže interferon alfa (vidjeti dio 4.8).
CNS effects, in particular depression, have been observed in some patients treated with ropeginterferon alfa-2b during the clinical development program (see section 4.8). 
Učinci na SŽS, posebice depresija, bili su opaženi u nekih bolesnika liječenih ropeginterferonom alfa2b tijekom programa kliničkog razvoja (vidjeti dio 4.8).
In the same study, a 25% increase in the AUC of theophylline (CYP1A2 substrate) was observed, demonstrating that pegylated interferon alfa-2a is an inhibitor of CYP1A2 activity. 
uočen je porast od 25% u AUC-u teofilina (supstrat CYP1A2) pokazujući da je pegilirani interferon alfa-2a inhibitor aktivnosti CYP1A2.
- if you have kidney problems. 
- ako imate problema s bubrezima.
Studies in rats with a similar interferon alfa medicinal product (pegylated interferon alfa-2a) showed a primarily elimination via hepatic metabolism. 
Ispitivanja na štakorima sa sličnim lijekovima koji sadrže interferon alfa (pegilirani interferon alfa-2a) pokazala su primarnu eliminaciju metabolizmom kroz jetru.
22 (12.4) 10.1 n.r. 
22 (12,4) 10,1 n.z.
*No CTCAE grade 4 (life-threating or disabling) or grade 5 (death) adverse reactions have been reported. 
n.z. *Nisu zabilježene nuspojave prema CTCAE stupnja 4 (po život opasne) ili stupnja 5 (smrt).
During ropeginterferon alfa-2b therapy, three cases of atrial fibrillation (1.1%; incidence rate: 0.5 events/100 patients per year) with intensity grade 1 to 3 occurred in two patients. 
Tijekom terapije ropeginterferonom alfa-2b dogodila su se tri slučaja atrijske fibrilacije (1,1%; stopa incidencije: 0,5 događaja/100 bolesnika na godinu) sa stupnjem intenziteta 1 do 3 u dva bolesnika.
Besremi contains less than 1 mmol sodium (23 mg) per mL, that is to say essentially ‘sodium-free'. 
Besremi sadrži manje od 1 mmol natrija (23 mg) po ml, tj. zanemarive količine natrija.
Mean % (± SD) 
Srednja vrijednost % (±SD)
Basedow's disease, sarcoidosis very rare idiopathic or thrombotic thrombocytopenic purpura# 
Basedowljeva bolest, sarkoidoza imunološkog sustava vrlo rijetko idiopatska ili trombotička trombocitopenična purpura#
The mean dose after 36 months of treatment (12-month treatment duration in the PROUD-PV Study and 24month treatment duration in the extension study) was 363 (±149) micrograms for ropeginterferon alfa2b. 
Srednja vrijednost veličine doze nakon 36 mjeseci terapije (12-mjesečno trajanje terapije u ispitivanju PROUD-PV te 24-mjesečno trajanje terapije u produžetku ispitivanja) iznosila je 363 (±149) mikrograma za ropeginterferon alfa-2b.
Sodium chloride Sodium acetate, anhydrous Acetic acid, glacial Benzyl alcohol Polysorbate 80 
Natrijev klorid Natrijev acetat, bezvodni Acetatna kiselina, ledena Benzilni alkohol Polisorbat 80
A reduced starting dose for ropeginterferon alfa-2b of 50 micrograms is recommended for patients with severe (GFR 1529 mL/min) renal impairment. 
Reducirana početna doza ropeginterferona alfa-2b od 50 mikrograma preporučuje se u bolesnika s teškim (GFR 15-29 ml/min) oštećenjem bubrega.
Recovered 
Oporavak
Besremi contains the active substance ropeginterferon alfa-2b, which belongs to the class of medicinal products called interferons. 
Besremi sadrži djelatnu tvar ropeginterferon alfa-2b, koji pripada skupini lijekova koji se zovu interferoni.
Please read this leaflet carefully before using the Besremi 250 micrograms pre-filled pen. 
Pažljivo pročitajte ovu uputu prije nego počnete koristiti Besremi 250 mikrograma napunjenu brizgalicu.
Patients who develop symptoms indicative of a thyroid dysfunction during ropeginterferon alfa-2b therapy, should evaluate their thyroid stimulating hormone (TSH) levels. 
Bolesnicima koji razviju simptome koji ukazuju na difunkciju štitnjače tijekom terapije ropeginterferonom alfa-2b, treba procijeniti njihove razine hormona koji stimulira štitnjaču (TSH).
(listed in section 6). 
(vidjeti dio 4.6).
The involvement of transport proteins in absorption, distribution and elimination of ropeginterferon alfa-2b is not known. 
Uključenost transportnih proteina u apsorpciju, distribuciju i eliminaciju ropeginterferona alfa-2b nije poznata.
It is unknown whether the active substance of the medicinal product is excreted in human milk. 
Nije poznato izlučuje li se djelatna tvar lijeka u majčino mlijeko.
Do not use this medicine if you notice that the pre-filled pen appears damaged, the solution is cloudy, has particles or flakes, or has any colour other than colourless to slightly yellow. 
Ovaj lijek se ne smije upotrijebiti ako primijetite da se brizgalica čini oštećena, otopina zamućena, sadrži čestice ili pahuljice ili joj je boja različita od bezbojne do svijetložute.
Pharmacokinetic interaction studies in humans with pegylated interferon alfa-2a indicated a moderate inhibitory effect on substrates metabolised by CYP1A2 and CYP2D6 (see section 4.5). 
Ispitivanja farmakokinetičkih interakcija u ljudi s pegiliranim interferonom alfa-2a ukazala su na umjereni inhbitorni učinak na supstrate koje metaboliziraju CYP1A2 i CYP2D6 (vidjeti dio 4.5).
• Do not use the pen if the solution is cloudy, has particles or flakes, or is any colour other than colourless to slightly yellow. 
• Nemojte koristiti brizgalicu ako je otopina zamućena, ima čestice ili pahuljice ili joj je boja različita od bezbojne do svijetložute.
Patient characteristics at screening in the PROUD-PV Study. 
Tablica 2. Karakteristike bolesnika pri probiru u ispitivanju PROUD-PV
• Optional: adhesive plaster 
• nije obavezno: flaster
250 μg, 300 μg, 350 μg, 400 μg, 450 μg and 500 μg. 
50 μg, 100 μg, 150 μg, 200 μg, 250 μg, 300 μg, 350 μg, 400 μg, 450 μg i 500 μg.
• Needle 
• iglu
Discontinuation of ropeginterferon alfa-2b should be considered in patients who develop new or worsening eye disorders. 
Prekid terapije ropeginterferonom alfa-2b treba uzeti u obzir kod bolesnika u kojih dođe do pojave novog ili pogoršanje postojećeg poremećaja oka.
The pharmacokinetic profile in patients with moderate or severe renal impairment and in patients with end stage renal disease (ESRD) has been evaluated only for other pegylated interferon alfa medicinal products. 
Oštećenje bubrega Farmakokinetički profil u bolesnika s umjerenim ili teškim oštećenjem bubrega sa završnim stadijem bolesti bubrega (engl. end stage renal disease, ESRD) procijenjen je samo za druge pegilirane interferone alfa.
Besremi is used as monotherapy for the treatment of polycythaemia vera in adults. 
Besremi se koristi kao monoterapija (samo jedan lijek u terapiji) za liječenje policitemije vere u odraslih.
Following multiple dosing of pegylated interferon alfa-2b (1.0 micrograms/kg subcutaneously administered every week for four weeks), the clearance of pegylated interferon alfa-2b was reduced by a mean of 17% and 44% in patients with moderate or severe renal impairment, respectively, compared to subjects with normal renal function. 
Nakon višekratnog doziranja pegiliranog interferona alfa-2b (1,0 mikrograma/kg supkutano primijenjeno svaki tjedan tijekom 4 tjedna), klirens pegiliranog interferona alfa-2b smanjen je za prosječno 17% te 44% u bolesnika s umjerenim ili teškim oštećenjem jetre u usporedbi s ispitanicima s normalnom bubrežnom funkcijom.
The response to ropeginterferon alfa-2b treatment is presented in Table 3 and Table 4. 
Odgovor na liječenje ropeginterferonom alfa-2b prikazan je u tablicama 3 i 4.
Uncommon side effects (may affect up to 1 in 100 people): - attempted suicide, thoughts about killing yourself - loss of vision which may be caused by bleeding in the retina (the retina is the light-sensitive layer in the eye), or by build-up of fat in or under the retina 
Manje česte nuspojave (mogu se javiti u do 1 na 100 osoba): - pokušaj samoubojstva, misli o samoubojstvu - gubitak vida koji može biti uzrokovan krvarenjem u mrežnici (mrežnica je sloj u oku osjetljiv na svjetlost) ili nakupljanjem masnoća u ili ispod mrežnice
Enzymes of the protein catabolism are considered to be involved in the metabolism of ropeginterferon alfa-2b. 
Smatra se da su enzimi koji sudjeluju u katabolizmu proteina uključeni u metabolizam ropeginterferona alfa-2b.